SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

o

Rule 13d-1(b)

o

Rule 13d-1(c)

x

Rule 13d-1(d)

CUSIP No.: 64049M209

1

Names of Reporting Persons:
Abbott Laboratories

2

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

o

3

SEC Use Only

4

Citizenship or Place of Organization:
State of Illinois

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5

Sole Voting Power:
865,558

6

Shared Voting Power:
0

7

Sole Dispositive Power:
865,558

8

Shared Dispositive Power:
0

9

Aggregate Amount Beneficially Owned by Each Reporting Person:
865,558

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11

Percent of Class Represented by Amount in Row 9:
1.7

12

Type of Reporting Person (See Instructions):
CO

Item 1(a).

Name of Issuer:
NeoGenomics, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices:
12701 Commonwealth Drive, Suite 9

Fort Myers, Florida 33913

Item 2(a).

Name of Person Filing:
Abbott Laboratories

Item 2(b).

Address of Principal Business Office or, if none, Residence:
100 Abbott Park Road

Dept. 322, Bldg. AP6A-2

Abbott Park, Illinois 60064-6049

Item 2(c).

Citizenship:
Not applicable.

Item 2(d).

Title of Class of Securities:
Common Stock

Item 2(e).

CUSIP Number:
64049M209

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

o

A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); and

(k)

o

Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____________________________.

Item 4.

Ownership.

Item 4(a)

Amount beneficially owned:   

865,558 shares

Item 4(b)

Percent of class:   

1.7%.

Item 4(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:   

865,558 shares.

(ii)

Shared power to vote or to direct the vote:    

0.

(iii)

Sole power to dispose or to direct the disposition of:   

865,558 shares.

(iv)

Shared power to dispose or to direct the disposition of:   

0.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.  x

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

Not applicable.

Dated: February 14, 2014

ABBOTT LABORATORIES

By:

/s/ Thomas C. Freyman

Name:

Thomas C. Freyman

Title:

Executive Vice President, Finance and

Chief Financial Officer